1. The current role of the heavy/light chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach
- Author
-
Ríos-Tamayo, R., Puig, Noemi, Algarín, Macarena, García de Veas Silva, José Luís, Barbosa, Nuno, Encinas, Cristina, Hernández, José Ángel, Alonso, Rafael, Campos, María Luisa, Rodríguez, Teresa, Leivas, Alberto, Olivares, María José, Sánchez, María José, Paiva, Bruno, Lahuerta, Juan José, Martínez-López, Joaquín, Ríos-Tamayo, R., Puig, Noemi, Algarín, Macarena, García de Veas Silva, José Luís, Barbosa, Nuno, Encinas, Cristina, Hernández, José Ángel, Alonso, Rafael, Campos, María Luisa, Rodríguez, Teresa, Leivas, Alberto, Olivares, María José, Sánchez, María José, Paiva, Bruno, Lahuerta, Juan José, and Martínez-López, Joaquín
- Abstract
Despite tremendous progress being made in recent years, multiple myeloma (MM) remains a challenging disease. The laboratory plays a critical role in the overall management of patients. The diagnosis, prognosis, clinical monitoring and evaluation of the response are key moments in the clinical care process. Conventional laboratory methods have been and continue to be the basis of laboratory testing in monoclonal gammopathies, along with the serum free light chain test. However, more accurate methods are needed to achieve new and more stringent clinical goals. The heavy/light chain assay is a relatively new test which can overcome some of the limitations of the conventional methods for the evaluation of intact immunoglobulin MM patients. Here, we report an update of the evidence accumulated in recent years on this method regarding its use in MM.
- Published
- 2021